

charles river | Valo

logica

transformative drug design



Redefining Your Drug Discovery Journey

How will you conquer the increasingly complex challenges that accompany the rapid pace of drug discovery innovation? We are transforming the drug discovery process to overcome these obstacles and guide you along your journey. Allow us to help you harness the potential of truly integrated AI-powered drug discovery

Embark on the transformational journey with us.

logica

transformative drug design

Charles River and Valo Health are transforming drug discovery with **Logica™**, a **customized turnkey drug discovery solution** from target to preclinical development. We increase certainty of small molecule drug discovery through delivery of advanceable leads and candidates, tying costs to value generation points.

You give us specifications; we deliver a drug candidate.

○ AI at the Center of Drug Discovery

Through the convergence of Valo's AI platform, and Charles River's world-class laboratory expertise, Logica seamlessly integrates molecular design capabilities and biological assay data in an **active learning loop** to build predictive models with industry leading accuracy.

We provide more insight into your leads leveraging the power of **hundreds** of *in vitro* and *in vivo* models in addition to **thousands** of computational predictive models.





Scan a broader universe of actionable chemistry and quickly iterate through **billions** of virtual molecules to rank and deliver novel results.

Increasing Certainty in Drug Discovery


This approach has a **90% success rate** in producing advanceable lead series. We'll also conduct an advancability assessment and leverage our data generation and compute capabilities to rapidly advance to a candidate.

Because we're confident in Logica's success, we've created a true risk sharing model where most of your **cost** is tied to success.



Better Leads, Better Drugs.

Starting with a broader universe of accessible chemical space, this integrated platform utilizes a learn-invent-optimize active learning loop to provide a lead series and then an optimized preclinical candidate. Unlike traditional offerings that focus on outsourcing specific discovery tasks, Logica aligns outputs to customer needs. This AI-powered drug discovery offering is comprised of two products: Logica-AL (Advancable Lead) and Logica-C (Candidate).



logica-AL

Customers obtain highly advanceable, potent series with desired characteristics such as ADME and selectivity, optimized for customer preferences and whose advancability has been extensively evaluated and simulated to maximize downstream probability of success.

- Potency
- Selectivity
- DMPK/ADME
- Off-target liabilities understood
- Structural Novelty
- Advancability assessment provided

logica-C

After Logica-AL, the Logica-C offering leverages promising chemical matter and program-optimized predictive models, to impact the success rate of each experiment, and rapidly advance the program. It delivers a development candidate that has undergone safety and efficacy tests, and is ready for IND enabling studies.

- Potency
- Efficacy
- Appropriate TI & human dose estimation
- Off targets and metabolites de-risked and understood
- CMC compatible routes
- Non-GLP MTD/DRF: Manageable or NOAEL

Rethink how you approach drug discovery; **Logica** can help you get to the clinic even faster by providing key insights, and more informed leads and candidates.

Partner with us to transform your drug discovery journey.

Info@Logica.AI • www.Logica.AI

 charles river | Valo